Press Releases

Press Releases
Date Title and Summary View
Apr 3, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) has received a Paragraph IV Notice Letter advising that Teva Pharmaceuticals USA, Inc. submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) seeking authorization from the FDA to manufacture an...
Apr 3, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, April 27, 2017 at 9 a.m. ET to discuss first quarter 2017 financial and operational results. The webcast can be accessed from the Investor Relations page at www.celgene.com. ...
Mar 5, 2017 Data from UNVEIL, the first trial of patients with moderate plaque psoriasis (BSA 5-10 percent) who were naïve to systemic and biologic therapy, presented at American Academy of Dermatology Congress OTEZLA demonstrated significant improvements versus placebo for the primary and key secondary ...
Mar 3, 2017 UNVEIL evaluated the efficacy and safety of oral OTEZLA at 16 weeks in patients with moderate plaque psoriasis who were naïve to systemic and biologic therapy SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced that findings from ongoing clinical t...
Mar 1, 2017 PDUFA date set for Aug. 30, 2017 SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals (NASDAQ:AGIO) today announced that the U.S. Food and Drug Administration (FDA) has accepted Celgene's New Drug Application (NDA) for enasidenib ...
Feb 27, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming investor conferences where Celgene management will provide an overview of the Company. The conferences will be webcast live and will be available in the Investor Relations section of the Company's website at www.cel...
Feb 24, 2017 Oral REVLIMID® is the first and only medicine licensed in Europe for use as post-autologous stem cell transplantation maintenance therapy in multiple myeloma The new indication expands the availability of REVLIMID® across the disease continuum of multiple myeloma ...
Feb 23, 2017 - Jacqualyn Fouse, Ph.D., to retire from Celgene effective June 30, 2017 and will not stand for reelection to the Celgene Board of Directors - Scott Smith to be promoted to President and Chief Operating Officer, effective April 1, 2017 - Terrie Curran to be promoted to President, G...
Feb 22, 2017 REVLIMID is the first and only treatment approved for maintenance following auto-HSCT Updated data from two large, randomized, controlled studies demonstrated median progression-free survival (PFS) advantages of 3.8 and 1.9 years, respectively, in favor of patients receiving REVLIMID comp...
Feb 17, 2017 Study met its primary endpoint in reducing annualized relapse rate (ARR) and measured secondary endpoints, compared to interferon (IFN) β-1a (Avonex®) Safety and tolerability consistent with phase II studies Confirmatory phase III RADIANCE trial data expected in Q2 of 201...
1
... NextLast
Add to Briefcase = add release to Briefcase